american diabetes association pancreatitis glp-1 receptor agonist history Addressing patient concerns about the 'newness' and long-term safety of agonists: A clinician's guide to counseling GLP-1 Agonists and Pancreatitis Risk

doi: 10.1161/atv.0000615456.97862.30 52 BanKNoyan-AshrafMHHoeferJBolzSSDruckerDJHusainM

9 , 29 , 30 , 31 In observational studies based on European and American study populations, however, the reported rates of discontinuation and addon therapy were much higher than reported in the randomized clinical trials

Can I lose 20 pounds in a month with GLP-1 injections

doi:10.1007/s00592-025-02525 71

Based on VigiBase, the World Health Organizations (WHO) adverse drug reaction database, intestinal obstructions are reported over 4.5 times more frequently with incretin-based drugs than with other diabetes medications [10]

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA